| Name | Title | Contact Details |
|---|---|---|
Michael Olszowy |
Chief Technology Officer | Profile |
Complexa is a clinical stage biopharmaceutical company focused on transforming the treatment of fibrosis and inflammation-associated orphan diseases. Leveraging its differentiated endogenous nitrated fatty acid cell signaling technology, Complexa is advancing a platform of agents which target fibrosis and inflammation across multiple orphan disease indications.
At Bionano Genomics®, we are committed to unlocking understanding of genome biology to advance the promise of genomics in areas including cancer and human disease, agricultural bioengineering and genome discovery. Our team is not afraid to venture into uncharted territory to look for answers. We welcome the curious and provide a place where those who are not satisfied with the status quo can feel at home. Our next-generation genome mapping and analysis tools help researchers see true genome structure to fill in what`s missing from sequencing-based data. Saphyr™, our high-speed, high-throughput whole genome mapping solution, offers unmatched structural variation discovery capabilities and the ability to construct the most complete genome assemblies. At Bionano, we are invested in the success of our customers and users around the world, and are dedicated to supporting them with the tools, resources and support they need to achieve their goals and make a real impact on improving quality of life for all.
We are a biotechnology leader that discovers, develops and delivers innovative therapies to improve the lives of patients with neurodegenerative diseases, hematologic conditions and autoimmune diseases. Patients worldwide benefit every day from our medicines for multiple sclerosis (MS) and hemophilia. Founded in 1978, we are one of the world’s oldest independent biotechnology companies. Our development pipeline is focused on areas of high unmet medical need, as we pursue new therapies for patients suffering from diseases with few or no treatment options. These include programs for secondary progressive MS, Alzheimer’s Disease, spinal muscular atrophy, lupus and amyotrophic lateral sclerosis (ALS), amongst others. With more than 7,500 people worldwide, we are truly a global organization, headquartered in Cambridge, Massachusetts, which is also home to our research operations. Our international headquarters are based in Zug, Switzerland and we have world-class manufacturing facilities in North Carolina and Denmark. We offer therapies globally through direct affiliate presence in 30 countries and a network of distribution partners in over 50 additional countries.
Chromatin is unlocking the potential of plants to produce greater value and meaningful products for consumers, growers, seed producers, and processors. At the same time, the company's technology can benefit the environment through decreased use of pesticides and fertilizers. The company's mini-chromosome technology simultaneously introduces multiple genetic traits into plants, reducing the time and cost required to develop improved and novel crop-based products, such as medicines, biomaterials, textiles and nutritionally improved foods. These products are enabled while allowing growers to enjoy the benefits of the most up-to-date agronomic traits, such as herbicide tolerance, pest resistance, and diseases resistance. Mini-chromosomes also provide unprecedented precision and control of new traits at every point in a plant's life cycle, from seed to field and beyond. Crop stewardship is at the core of Chromatin's values, and the company is equally focused on using its technology to introduce sustainable, healthy agricultural practices while enhancing commercial value and quality of life.
Elco Laboratories Inc is a University Park, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.